Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 25;16(4):670-675.
doi: 10.18502/jovr.v16i4.9757. eCollection 2021 Oct-Dec.

Side Effects of Brolucizumab

Tahmineh Motevasseli  1   2   3 , Saeed Mohammadi  4   5 , Fatemeh Abdi  6 , William R Freeman  2   3
Affiliations
Review

Side Effects of Brolucizumab

Tahmineh Motevasseli et al. J Ophthalmic Vis Res. .

Erratum in

  • Erratum: Side Effects of Brolucizumab.
    [No authors listed] [No authors listed] J Ophthalmic Vis Res. 2022 Jan 21;17(1):157. doi: 10.18502/jovr.v17i1.10185. eCollection 2022 Jan-Mar. J Ophthalmic Vis Res. 2022. PMID: 35194510 Free PMC article.

Abstract

Age-related macular degeneration and its complication, subretinal neovascularization, are common causes of progressive, irreversible impairment of central vision. Anti-vascular endothelial growth factor (anti-VEGF) therapy has improved the visual outcome and provided an evolution in the treatment of retinal disease. The current four anti-VEGF drugs - pegaptanib, ranibizumab, aflibercept, and bevacizumab - have been administered for many years. A new anti-VEGF agent, brolucizumab, was approved by the U.S. Food and Drug Administration (FDA) in late 2019 for the treatment of wet age-related macular degeneration. Brolucizumab is a novel single-chain fragment variable antibody that inhibits all isoforms of VEGF-A and has been suggested to have more tissue penetration. Despite all the benefits, there are some reports of serious side effects that need to be understood in managing patients. Brolucizumab has been reported to cause occlusive retinal vasculitis in the setting of intraocular inflammation, which has not been seen in other anti-VEGF medications. A PubMed and Scopus search was performed and all article types were included. In the present article, we have reviewed the reported side effects of brolucizumab.

Keywords: Brolucizumab; Wet Age-related Macular Degeneration; Anti-vascular Endothelial Growth Factor.

PubMed Disclaimer

References

    1. Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2014;2:e106–e116. - PubMed
    1. Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR, Group VISiONCT. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805–2816. - PubMed
    1. Comparison of Age-related Macular Degeneration Treatments Trials Research G, Writing C, Martin DF, Maguire MG, Fine SL, Ying GS, et al. 3. Comparison of Age-related Macular Degeneration Treatments Trials Research G, Writing C, Martin DF, Maguire MG, Fine SL, Ying GS, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2020;127:S135–S145. - PubMed
    1. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–2548. - PubMed
    1. Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K, Group S-US. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP) Ophthalmology. 2013;120:2292–2299. - PubMed